New Insights into Multiple Myeloma Prognostication After Autologous Stem Cell Transplantation

Strategic Insights -

Researchers from Capital Medical University have conducted a retrospective cohort study to evaluate the prognostic impact of baseline variables on survival after autologous stem cell transplantation in multiple myeloma patients. The study, published in Transplant Immunology, analyzed data from 350 patients who underwent a first autologous hematopoietic stem cell transplantation (auto-HSCT) between 2001 and 2019 at Beijing Chao-Yang Hospital. The researchers aimed to refine risk stratification and improve prognostication by evaluating the independent predictive roles of pretreatment hemoglobin (Hb) levels, myeloma subtype, and specific induction regimens.

Key Takeaways:

  • The study revealed that pretreatment hemoglobin (Hb) levels, myeloma subtype, and specific induction regimens are independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma patients.
  • The researchers found that Hb levels below 110 g/L were associated with inferior survival outcomes, while patients with higher Hb levels had improved survival rates.
  • Myeloma subtype was also a significant prognostic factor, with patients with IgG myeloma having a better prognosis than those with IgA or light-chain myeloma.
  • The study also highlighted the importance of specific induction regimens, with patients receiving lenalidomide-based induction therapy experiencing better outcomes than those receiving bortezomib-based therapy.
  • The researchers concluded that integrating these factors into prognostic models could help better tailor therapeutic strategies and manage patient expectations.

Statistics:

  • A total of 350 multiple myeloma patients were included in the study, with a median age of 55 years (range 23-73 years).
  • The median follow-up duration was 50 months (range 3-146 months).
  • The 5-year overall survival rate for patients with Hb levels below 110 g/L was 44.1%, compared to 65.6% for those with Hb levels above 120 g/L.
  • Patients with IgG myeloma had a 5-year overall survival rate of 74.2%, compared to 52.3% for those with IgA or light-chain myeloma.
  • Patients receiving lenalidomide-based induction therapy had a 5-year overall survival rate of 72.1%, compared to 56.3% for those receiving bortezomib-based therapy.

Sources:

  • Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: A retrospective cohort study. Transplant Immunology, 2025:102305.
  • NewsRx. New Multiple Myeloma Findings Has Been Reported by Researchers at Capital Medical University (Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell ...). Hematology Week. October 20, 2025; p 1125.